Research Spotlight:

Pharma Production Digital Transformation

The Pharma Production Digital Transformation Research Spotlight provides access to all research related to this topic. This Spotlight includes:

  • All research outlined below
  • Any updates to the research six months from purchase
  • 60 minutes of analyst inquiry to speak to an analyst
Purchase

Included Research

Digital Transformation of the Pharmaceutical Supply Chain
Digital Transformation of the Pharmaceutical Supply Chain
 Research Report | 1Q 2023 | AN-5733
Table of Contents

1. EXECUTIVE SUMMARY

2. THE PHARMACEUTICAL SUPPLY CHAIN

2.1. MARKET OVERVIEW
2.2. CONTEMPORARY CHALLENGES
2.3. PHARMACEUTICAL REGULATION

3. STRATEGIC GUIDANCE

3.1. STRATEGIC GUIDANCE FOR TECHNOLOGY VENDORS
3.2. STRATEGIC GUIDANCE FOR END USERS

4. TECHNOLOGY OVERVIEW

4.1. CONTROL TOWERS
4.2. BLOCKCHAIN
4.3. PRODUCT TRACEABILITY AND THE INTERNET OF THINGS (IOT)
4.4. AUTOMATED STORAGE AND RETRIEVAL SYSTEMS
4.5. ROBOTIC PICKING

5. DRIVERS & INHIBITORS OF DIGITAL TRANSFORMATION

5.1. DRIVERS
5.2. INHIBITORS
6. CASE STUDIES
7. FORECASTS

8. COMPANY PROFILES

8.1. MOTIVE
8.2. OPTEL
8.3. RIGHTHAND ROBOTICS
8.4. SNAPFULFIL
8.5. WILIOT
Critical Questions Answered
  • How should pharmaceutical companies approach their digital transformation strategies?
  • What pain points can deeper asset visibility, control towers, blockchain, and robotics help resolve?
  • What is the expected growth of the pharmaceutical industry and the investment in digital transformations by region?
Research Highlights
  • Overview of the challenges faced by the pharmaceutical industry, emerging trends, and key regulations.
  • Analysis of the drivers and inhibitors of digital transformations for pharmaceutical companies and retailers.
  • Applications of technologies to the pharmaceutical industry and their impacts on operations.
full contents...
Software Suppliers Supporting the Pharmaceuticals Value Chain
Software Suppliers Supporting the Pharmaceuticals Value Chain
 Presentation | 4Q 2022 | PT-2532
Table of Contents

Introduction

Factors Affecting the Pharmaceutical Value Chain and the Use of Software

Innovators Supporting the Drug Discovery and Preclinical Stages 

Innovators Supporting Clinical Trial Programs 

Innovators Supporting Pharma Manufacturing Operations 

Critical Questions Answered
  • What are the key focus areas for software suppliers when engaging with different parts of the pharmaceutical value chain?
  • What drives and inhibits investments in software solutions.
  • The main tenants of vendors’ solutions and ABI Research’s thoughts on how well they meet market requirements.
Research Highlights
  • Concise backdrop to how software supports pharmaceutical firms’ efforts to bring drugs to market sooner, while remaining regulatory compliant.
  • Profiles of 12 vendors looking to improve the lives of practitioners in laboratories, those running clinical trials, and those tasked with producing the drugs, medicines, and vaccines.
  • An “ABI Research Verdict” on each vendor’s solution.
full contents...
IoT and Supply Chain Visibility in the Pharmaceutical Industry: Ecosystem Assessment
IoT and Supply Chain Visibility in the Pharmaceutical Industry: Ecosystem Assessment
 Research Report | 1Q 2022 | AN-5352
Table of Contents

1. EXECUTIVE SUMMARY

2. THE PHARMACEUTICAL INDUSTRY: MAPPING AND DESCRIPTION

2.1. Overview of Pharmaceutical Supply Chain
2.2. Product Types
2.3. Countries
2.4. Regulatory Environment

3. TRACKING AND MONITORING OPPORTUNITY ASSESSMENT

3.1. Pain Points and Use Cases
3.2. Technology Landscape
3.3. Software Types
3.4. Data Carrier and Hardware Types
3.5. Tracker Device Features
3.6. Changes in Technology Environment
3.7. Asset Visibility: Opportunities and Challenges
3.8. Recommendations
3.9. Market Sizing
Critical Questions Answered
  • What are the main technologies that will drive supply chain visibility in the pharmaceutical industry?
  • What types of assets and products are being tracked, and for what reason?
  • What are the challenges that are being faced in the pharmaceutical supply chain, and how is visibility helping to solve them?
Research Highlights
  • Forecasts of the TAM and SAM of the pharmaceutical supply chain visibility market.
  • Mapping and detailed description of pain points and use-cases requiring tracking and visibility in the pharmaceutical supply chain.
  • View of geographies, products, and technologies that will drive change in the pharmaceutical supply chain.
full contents...
Digital Transformation in the Pharmaceutical Industry
Digital Transformation in the Pharmaceutical Industry
 Research Report | 1Q 2021 | AN-5422
Table of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION TO THE PHARMACEUTICAL MARKET

2.1. Regulatory Environment

3. COMPONENTS OF A DIGITAL STRATEGY IN PHARMA MANUFACTURING

4. STRATEGIC GUIDANCE/RECOMMENDATIONS FOR STAKEHOLDERS

4.1. For Pharmaceutical Manufacturers
4.2. For Technology Suppliers

5. INDUSTRY 4.0 DRIVERS

6. INDUSTRY 4.0 INHIBITORS

7. MARKET DEVELOPMENTS

8. FORECASTS

9. PHARMACEUTICAL MANUFACTURING SUPPLIER ECOSYSTEM

9.1. Digitizing Processes
9.2. Optimizing Production Processes
Critical Questions Answered
  • What are the current and future trends concerning technology adoption by pharmaceutical manufacturers?
  • What is the influence of regulators both in terms of compliance and their encouragement of investments in digital technologies?
  • What issues inhibit pharmaceutical manufacturers to invest in digital technologies and potential ways they could be overcome?
  • Who are some of technology suppliers that focus on addressing the specific needs of pharmaceutical manufacturers?
Research Highlights
  • Strategic recommendations about engaging with pharmaceutical manufacturers.
  • A detailed assessment of spend by pharmaceutical manufacturers on digital technologies through 2030.
  • Case studies covering how manufacturers have utilized digital technologies.
  • Understand the types of suppliers looking to help pharmaceutical manufacturers digitize processes and optimize production.
full contents...
Pfizer: Lessons Learned from Upscaling Production from 200 Million to 3 Billion Vaccines
Pfizer: Lessons Learned from Upscaling Production from 200 Million to 3 Billion Vaccines
 Insight | 1Q 2023 | IN-6851
Up until the pandemic, Pfizer produced in the region of 200 million vaccines per annum. Once the company’s mRNA vaccine was approved by regulators, attention turned to getting the vaccine to as many people around the world as possible. The urgency to thwart the effects of the pandemic trumped many of the deliberations that occur in calmer times. Today, manufacturers have to cope with the lingering effects of the pandemic, along with geopolitical tensions and economic pressures. Many of the measures taken by Pfizer were only applicable at a time of acute stress, while others have applications going forward. It’s critical for manufacturers and suppliers to understand the difference.
Asset Visibility: Changing Regulatory Landscape Driving Adoption of IoT Solutions in the Pharma Vertical
Asset Visibility: Changing Regulatory Landscape Driving Adoption of IoT Solutions in the Pharma Vertical
 Insight | 1Q 2022 | IN-6494
This insight briefly outlines the regulatory changes in the pharma market and explores how serialization regulations are impacting IoT use cases. The insight then explains which geographic markets are already mature and which are less penetrated.